{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Post+ET+MF&page=2",
    "query": {
      "condition": "Post ET MF",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Post+ET+MF&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:45:49.868Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04485260",
      "title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "KRT-232",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kartos Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 36,
      "start_date": "2021-01-28",
      "completion_date": "2024-10",
      "has_results": false,
      "last_update_posted_date": "2022-05-09",
      "last_synced_at": "2026-05-22T09:45:49.868Z",
      "location_count": 8,
      "location_summary": "Duarte, California • Baltimore, Maryland • Ann Arbor, Michigan + 5 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04485260"
    },
    {
      "nct_id": "NCT01981850",
      "title": "A Phase 2 Study of RO7490677 In Participants With Myelofibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Polycythemia Vera",
        "Post-Essential Thrombocythemia Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "RO7490677",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2013-10-01",
      "completion_date": "2020-07-10",
      "has_results": true,
      "last_update_posted_date": "2022-01-05",
      "last_synced_at": "2026-05-22T09:45:49.868Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01981850"
    },
    {
      "nct_id": "NCT03935555",
      "title": "Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Primary Myelofibrosis (PMF)",
        "Post-Polycythemia Vera Myelofibrosis (Post-PV MF)",
        "Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)"
      ],
      "interventions": [
        {
          "name": "PU-H71",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Samus Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2019-08-12",
      "completion_date": "2022-11-04",
      "has_results": false,
      "last_update_posted_date": "2022-11-17",
      "last_synced_at": "2026-05-22T09:45:49.868Z",
      "location_count": 3,
      "location_summary": "Larkspur, California • Los Angeles, California • Houston, Texas",
      "locations": [
        {
          "city": "Larkspur",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03935555"
    },
    {
      "nct_id": "NCT05279001",
      "title": "A Safety and Tolerability Study of Jaktinib",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Jaktinib Hydrochloride Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Suzhou Zelgen Biopharmaceuticals Co.,Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2024-07-01",
      "completion_date": "2025-11-30",
      "has_results": false,
      "last_update_posted_date": "2024-03-21",
      "last_synced_at": "2026-05-22T09:45:49.868Z",
      "location_count": 1,
      "location_summary": "Canton, Ohio",
      "locations": [
        {
          "city": "Canton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05279001"
    },
    {
      "nct_id": "NCT06327100",
      "title": "Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Post-polycythemia Vera Myelofibrosis",
        "Post-Essential Thrombocytosis Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Tasquinimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2024-08-01",
      "completion_date": "2031-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-05-22T09:45:49.868Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06327100"
    },
    {
      "nct_id": "NCT00910728",
      "title": "Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Primary Myelofibrosis (PMF)",
        "Post-Polycythaemia Vera",
        "Essential Thrombocythaemia Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "AZD1480",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "25 Years to 99 Years"
      },
      "enrollment_count": 65,
      "start_date": "2009-05",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2017-04-24",
      "last_synced_at": "2026-05-22T09:45:49.868Z",
      "location_count": 2,
      "location_summary": "New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00910728"
    },
    {
      "nct_id": "NCT04640532",
      "title": "KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis",
        "Post-PV MF",
        "Post-ET Myelofibrosis",
        "Primary Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "KRT-232",
          "type": "DRUG"
        },
        {
          "name": "TL-895",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kartos Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 116,
      "start_date": "2020-11-17",
      "completion_date": "2025-07-24",
      "has_results": false,
      "last_update_posted_date": "2022-05-09",
      "last_synced_at": "2026-05-22T09:45:49.868Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Whittier, California • Lake City, Florida + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Lake City",
          "state": "Florida"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Fort Lee",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04640532"
    },
    {
      "nct_id": "NCT06479135",
      "title": "Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myelofibrosis",
        "Post-PV MF",
        "Post-ET Myelofibrosis",
        "Primary Myelofibrosis",
        "MF"
      ],
      "interventions": [
        {
          "name": "Navtemadlin",
          "type": "DRUG"
        },
        {
          "name": "Navtemadlin placebo",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kartos Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2024-06-03",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-05-22T09:45:49.868Z",
      "location_count": 58,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 52 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06479135"
    },
    {
      "nct_id": "NCT07362225",
      "title": "MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Polycythemia Vera",
        "ET (Essential Thrombocythemia)",
        "Polycythemia Vera (PV)",
        "Essential Thrombocythemia (ET)",
        "Primary Myelofibrosis (MF)",
        "Primary Myelofibrosis (PMF)",
        "Myelofibrosis",
        "Myelofibrosis (MF)",
        "Myelofibrosis, Primary",
        "Myelofibrosis, Post ET",
        "Myelofibrosis, Post PV",
        "Myelofibrosis (PMF)",
        "Myelofibrosis，MF",
        "Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis",
        "Myelofibrosis Due to and Following Polycythemia Vera",
        "Myelofibrosis Transformation in Essential Thrombocythemia",
        "Myelofibrosis With High Molecular Risk Mutations",
        "MF",
        "Secondary Myelofibrosis",
        "Secondary Myelofibrosis in Myeloproliferative Disease",
        "Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)",
        "Post-Polycythemia Vera Myelofibrosis",
        "Post-polycythemia Vera Myelofibrosis (PPV-MF)",
        "Post-polycythemia Vera Myelofibrosis (Post-PV MF)",
        "Post-polycythemia Vera Myelofibrosis(Post-PV MF)",
        "Post-PV MF",
        "Post-Essential Thrombocythemia Myelofibrosis",
        "Post-essential Thrombocythemia Myelofibrosis (PET-MF)",
        "Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)",
        "Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)",
        "Post-ET MF",
        "Pre-fibrotic Myelofibrosis",
        "Myeloproliferative Disorder",
        "Myeloproliferative Disorders",
        "Myeloproliferative Disorders (MPD)",
        "Myeloproliferative Neoplasms (MPNs)",
        "Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis",
        "Myeloproliferative Neoplasm With 10% Blasts or Higher",
        "Myeloproliferative Neoplasms",
        "MPN",
        "MPN (Myeloproliferative Neoplasms)",
        "MPN-associated Myelofibrosis",
        "Myeloproliferative Neoplasm, Unclassifiable",
        "Myeloproliferative Neoplasm, Not Otherwise Specified",
        "Accelerated Phase MPN",
        "Accelerated Phase Myeloproliferative Neoplasm",
        "Blast Phase MPN",
        "Blast Phase Myeloproliferative Neoplasm",
        "Thrombocythemia Myelofibrosis (PET-MF)",
        "Thrombocythemia, Essential",
        "Thrombocythemia, Hemorrhagic",
        "Agnogenic Myeloid Metaplasia",
        "Chronic Idiopathic Myelofibrosis",
        "Idiopathic Myelofibrosis",
        "MDS/MPN Crossover Syndromes"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "MPN Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5000,
      "start_date": "2025-09-26",
      "completion_date": "2035-09-08",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-05-22T09:45:49.868Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • New York, New York",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07362225"
    },
    {
      "nct_id": "NCT05835466",
      "title": "Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis (PMF)",
        "Post Essential Thrombocythemia Myelofibrosis (ET-MF)",
        "Post Polycythemia Vera Related Myelofibrosis (PV-MF)"
      ],
      "interventions": [
        {
          "name": "reparixin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2023-07-24",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-05-22T09:45:49.868Z",
      "location_count": 9,
      "location_summary": "Tampa, Florida • Atlanta, Georgia • Buffalo, New York + 4 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05835466"
    }
  ]
}